ZEGALOGUE (AUTOINJECTOR)
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZEGALOGUE (AUTOINJECTOR) (ZEGALOGUE (AUTOINJECTOR)).
Zegalogue (dasiglucagon) is a glucagon analog that binds to glucagon receptors, activating adenylate cyclase and increasing cAMP levels, which promotes glycogenolysis and gluconeogenesis in the liver, thereby raising blood glucose levels.
| Metabolism | Primarily metabolized via proteolytic degradation into small peptides and amino acids; not metabolized by CYP450 enzymes. |
| Excretion | Primarily hepatic metabolism followed by biliary and fecal excretion, with negligible renal elimination (<2%). |
| Half-life | 50–65 minutes (terminal elimination half-life). |
| Protein binding | Negligible (<5%); not significantly bound to plasma proteins. |
| Volume of Distribution | 0.3–0.5 L/kg, indicating distribution primarily in extracellular fluid. |
| Bioavailability | 100% after intramuscular injection (autoinjector). |
| Onset of Action | Within 1 minute after intramuscular administration. |
| Duration of Action | Approximately 20–30 minutes based on clinical efficacy in reversing neuromuscular blockade. |
| Molecular Weight | 4119.9 |
0.25 mg intramuscularly (IM) as a single dose into the anterolateral thigh, repeated once after 15 minutes if necessary.
| Dosage form | SOLUTION |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Weight-based dosing: 0.01 mg/kg IM (maximum 0.25 mg) into the anterolateral thigh, repeated once after 15 minutes if necessary. |
| Geriatric use | No specific adjustment required; monitor for adverse effects due to potential comorbidities. |
| 1st trimester | Insufficient human data; animal studies not available. Theoretical risk of maternal hypotension and fetal hypoxia during severe hypoglycemia treatment. Avoid unless clearly needed. |
| 2nd trimester | Insufficient human data; potential for maternal hypotension and fetal distress during severe hypoglycemia. Use only if benefit outweighs risk. |
| 3rd trimester | Insufficient human data; risk of maternal hypotension and fetal distress. Use only in emergency severe hypoglycemia not responding to standard therapy. |
Clinical note
Comprehensive clinical and safety monograph for ZEGALOGUE (AUTOINJECTOR) (ZEGALOGUE (AUTOINJECTOR)).
| Placental transfer | Unknown; likely negligible due to high molecular weight and rapid degradation, but no specific studies exist. |
| Breastfeeding | No data on presence in human milk; likely minimal systemic absorption due to rapid hepatic clearance. Caution if used in breastfeeding women, but may be acceptable for emergency treatment. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to dasiglucagon or any excipientPheochromocytoma (risk of hypertensive crisis)Insulinoma (risk of hypoglycemia rebound)
| Precautions | Risk of hypoglycemia due to overdose or inadequate response, Risk of nausea and vomiting, Risk of hypersensitivity reactions including anaphylaxis, Risk of hyperglycemia in patients with pheochromocytoma or insulinoma |
| Food/Dietary | No specific food interactions. However, after successful treatment, patients should consume fast-acting carbohydrates to stabilize blood glucose levels and prevent recurrent hypoglycemia. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Zegalogue (dasiglucagon) is a glucagon analog; no adequate human studies exist. In animal reproduction studies, no evidence of fetal harm was observed at doses up to 600 times the MRHD. Risk cannot be ruled out; use only if clearly needed. First trimester: limited data; theoretical risk of hyperglycemia-related effects if maternal hypoglycemia not corrected. Second and third trimesters: same as first; no known teratogenicity. |
| Fetal Monitoring | Monitor maternal blood glucose frequently during and after administration. Fetal heart rate monitoring recommended if maternal severe hypoglycemia occurs, as it may cause fetal distress. Assess for uterine contractions if given near term. |
| Fertility Effects | No human data on fertility. Animal studies (rats) showed no impairment of fertility at doses up to 600 times MRHD. Theoretical risk from maternal hypoglycemia on conception/early pregnancy. |
| Zegalogue (dasiglucagon) is a glucagon analog indicated for severe hypoglycemia in diabetes patients aged 6 years and older. It is administered via autoinjector into the lower abdomen, outer thigh, or outer upper arm. Unlike reconstituted glucagon, it is stable in liquid form, allowing for rapid administration without reconstitution. Onset of action is within 10-15 minutes. Patients may experience nausea and vomiting; risk can be reduced by lying patient on side to prevent aspiration. Ensure patient has received carbohydrate intake once conscious to prevent recurrent hypoglycemia. |
| Patient Advice | Use only for severe hypoglycemia where the patient is unable to take oral carbohydrates. · Inject into the lower abdomen, outer thigh, or outer upper arm through clothing if necessary. · Do not use if the solution is discolored or contains particles. · After injection, call emergency medical services immediately. · Turn patient on their side to prevent choking if vomiting occurs. · Once conscious, give fast-acting sugar (e.g., fruit juice, glucose tablets) to prevent recurrence. · Store at room temperature; do not freeze or expose to heat above 30°C (86°F). · Check expiration date before use. |